late effect surveillance following allosct: the publication of new guidelines
Published 4 months ago • 35 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
1:59
the rapid evolution of myeloma research & the importance of improving drug accessibility
-
0:58
current research and next steps to improve the understanding and management of icaht
-
1:26
the future of jak inhibition for mpns
-
1:17
exciting novel treatments being developed for mds
-
21:32
yearly covid vaccine, how compelled am i?
-
3:37
mds aplastic anemia,platelets bleeding gums & while coughing hemoptysis homeopathic treatment best
-
1:01:06
[recorded webinar] protac — developing new therapies through targeted protein degradation
-
2:41
an overview of the latest advances in hematology
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:38
considerations when selecting between jak inhibitors for patients with mpns
-
5:06
considerations for drug development in hematological oncology
-
0:45
current landscape of treatment for scd: an update from ash 2023
-
1:08
insights into disease-modifying agents being explored in mpns
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
1:07
the second revision of the international staging system for os in mm
-
4:44
keynote-183 and optimismm: creating new standards of care for r/r mm
-
4:18
novel drugs in the r/r mm: imids
-
1:34
are thrombotic risk and progression in et predictable?
-
1:42
applying next-generation sequencing in the diagnosis of rare inherited anemias
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
2:41
targeting bclxl in mpns: current perspectives and future outlooks